Amanta Healthcare Limited has successfully completed its scheduled meeting with analysts and institutional investors, following through on its commitment to stakeholder engagement and regulatory compliance. The company has formally notified stock exchanges about the outcome of this interaction as part of its ongoing transparency initiatives.

Meeting Execution and Outcome

The company successfully conducted the comprehensive meeting with analysts and institutional investors on April 7, 2026, as previously scheduled. The meeting took place at Kheda, Gujarat, featuring both group discussions and a site visit that provided participants with firsthand insights into the company's operations.

Regulatory Compliance and Information Sharing

The meeting outcome notification was submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's adherence to regulatory frameworks. This notification was made in reference to the earlier intimation dated April 2, 2026.

During the interaction, company officials maintained strict compliance with insider trading regulations. The company has specifically confirmed that only publicly available information was shared during the meeting, with no Unpublished Price Sensitive Information (UPSI) being discussed or disclosed to participants.

Corporate Governance and Communication

The outcome notification was signed by Nikhita Dinodia, Company Secretary and Compliance Officer, with digital signature authentication dated April 9, 2026. This demonstrates proper corporate governance protocols and authorized communication channels for regulatory disclosures.

The company maintains its registered and corporate office at 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad, Gujarat, with established communication channels including dedicated telephone and email contact points for stakeholder engagement.

Amanta healthcare Limited has filed its mandatory quarterly compliance certificate with the Bombay Stock Exchange and National Stock Exchange of India for the quarter ended March 31, 2026. The submission, dated April 8, 2026, fulfills the company's regulatory obligations under SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Submission

The certificate was submitted pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Company Secretary and Compliance Officer Nikhita Dinodia signed the submission on behalf of Amanta Healthcare Limited, ensuring adherence to prescribed timelines for regulatory filings.

Registrar Confirmation Certificate

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, served as the company's Registrar and Share Transfer Agent for the quarter. The registrar, holding SEBI Registration No. INR000004058, issued the confirmation certificate dated April 1, 2026.

Sr. Vice President-Corporate Registry Ashok Shetty signed the registrar's certificate, confirming compliance with dematerialization procedures. The certificate validates that all securities received from depository participants during the quarter were properly processed within prescribed timelines.

Dematerialization Process Compliance

The registrar confirmed several key compliance aspects for the quarter:

• Securities received for dematerialization were confirmed to depositories
• All security certificates were properly accepted or rejected
• Listed securities maintained consistency with existing stock exchange listings
• Security certificates were mutilated and cancelled after verification
• Depository names were substituted in the register of members

Corporate Information

Amanta Healthcare Limited operates from its registered and corporate office located at 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad-380058, Gujarat. The company maintains its corporate identification number as L24139GJ1994PLC023944, reflecting its incorporation status in Gujarat.

The filing demonstrates the company's commitment to maintaining regulatory compliance and transparent communication with stock exchanges and regulatory authorities.